 1SPONSOR: The University of Chicago  
 PROTOCOL TITLE : A phase II prospective, open-label trial of perioperative combination 
nivolumab and ipi[INVESTIGATOR_799127].  
 Principal Investigator: [INVESTIGATOR_799128], MD,  Professor of Medicine Section of Hematology/Oncology, Univer sity of Chicago Medical Center 
Tel: [PHONE_16682] [EMAIL_15215]  
 
Co-Investigators: Divya Sood, MD Kiran Turaga, MD, MPH Aliya Husain, MD Oliver Eng, MD Samuel Armato, PhD Michael Drazer, MD Ankit Dhiman, MBBS Emily Fenton, PA Aytekin Oto, MD, MBA Carla Harmath, MD Aditya Juloori, MD  
Statistician: Mihai Giurcanu, PhD 
 Amendment: 4 Protocol Version Da te: September 21, [ADDRESS_1102175] Identification  & Recruitment  ..................................................................................  14 
4.6 Location ..............................................................................................................................  14 
4.7 Discontinuation  of Study and Participant  Withdrawal  .........................................................  14 
5.0 TRIAL INTERVENTIONS  ................................................................................................  15 
5.1 Pre‐intervention  Testing .....................................................................................................  15 
5.2 Neoadjuvant  Nivolumab  and Ipi[INVESTIGATOR_125]  ............................................................................  15 
5.2.1 Drug Supply ............................................................................................................................... ............. 15 
5.2.2 Dose Selection ............................................................................................................................... ........ 15 
5.2.3 Dose Modification  ............................................................................................................................... ... 16 
5.3 Surgical Intervention  ...........................................................................................................  16 
5.4 Adjuvant  Nivolumab  and Ipi[INVESTIGATOR_125]  ..................................................................................  17 
6.0 ADDITIONAL  METHODOLOGY  ......................................................................................  17 
6.1 Trial Blinding/Masking  ........................................................................................................  17 
6.2 Randomization  or Treatment  Allocation  .............................................................................  17 
 36.3 Stratification  .......................................................................................................................  17 
6.4 Concomitant  Medications/Vaccinations  (allowed & prohibited)  .........................................  17 
6.4.1 Acceptable  Concomitant  Medications  ...................................................................................................  17 
6.4.2 Prohibited  Concomitant  Medications  ....................................................................................................  18 
6.5 Supportive  Care Guidelines  .................................................................................................  18 
6.6 Diet/Activity/Other  Considerations  ....................................................................................  [ADDRESS_1102176] Withdrawal/Discontinuation  Criteria ......................................................................  22 
6.8 Clinical Criteria for Early Trial Termination  ..........................................................................  22 
7.0 TRIAL PROCEDURES  .....................................................................................................  23 
7.1 Flow Chart – Schedule  of Events ..........................................................................................  [ADDRESS_1102177]‐Treatment  Phases ............................................................................  25 
7.2 Informed  Consent ...............................................................................................................  26 
7.3 Inclusion/Exclusion  Criteria Review.....................................................................................  26 
7.4 Medical History ...................................................................................................................  26 
7.5 Prior and Concomitant  Medications  Review ........................................................................  26 
7.5.1 Prior Medications  ............................................................................................................................... ... 26 
7.5.2 Concomitant  Medications.................................................................................................................... .. 27 
7.6 Disease Details and Treatments  ..........................................................................................  27 
7.6.1 Disease Details ............................................................................................................................... ........ 27 
7.6.2 Prior Treatment  Details .........................................................................................................................  27 
7.6.3 Subsequent  Anti‐Cancer Therapy Status ...............................................................................................  27 
7.7 Adverse Event (AE) Monitoring  ...........................................................................................  27 
7.8 Full Physical Exam ...............................................................................................................  27 
7.9 Vital Signs ...........................................................................................................................  27 
7.10 Eastern Cooperative  Oncology  Group (ECOG) Performance  Scale ........................................  28 
7.11 Tumor Imaging and Assessment  of Disease .........................................................................  28 
7.12 Tumor Tissue Collection  and Correlative  Studies Blood Sampling  ........................................  28 
7.13 Laboratory  Procedures/Assessments  ..................................................................................  28 
7.14 Safety Follow‐Up Visit .........................................................................................................  29 
7.15 Follow‐up Visits ..................................................................................................................  29 
7.16 Survival Follow‐up ..............................................................................................................  [ADDRESS_1102178] .......................................................................................................  34 
9.2 Packaging  and Labeling Information  ....................................................................................  34 
9.3 Clinical Supplies Disclosure  .................................................................................................  34 
9.4 Storage and Handling Requirements  ...................................................................................  34 
10.0 ADMINISTRATIVE  AND REGULATORY  DETAILS ............................................................  34 
10.1 Confidentiality  ....................................................................................................................  34 
10.2 Compliance  with Financial Disclosure  Requirements  ...........................................................  34 
10.3 Compliance  with Law, Audit and Debarment  ......................................................................  35 
10.4 Compliance  with Trial Registration  and Results Posting Requirements  ................................  35 
10.5 Quality Management  System ..............................................................................................  35 
10.6 Data Management  ..............................................................................................................  35 
11.0 REFERENCES  ................................................................................................................  35 
12.0 APPENDIX  ...................................................................................................................  40 
12.1 ECOG Performance  Status ...................................................................................................  40 
12.2 Common  Terminology  Criteria for Adverse Events V5.0 (CTCAE) .........................................  40 
12.3 Prescribing  Information  ......................................................................................................  40 
12.3.1  Nivolumab  ............................................................................................................................... .......... 40 
12.3.2  Ipi[INVESTIGATOR_125]..................................................................................................................... ....................  40 
12.4 EORTC QOL‐C30 Quality of Life Survey ................................................................................  40 
 
 
 
TRIAL SUMMARY 
Abbreviated Title Nivolumab and Ipi[INVESTIGATOR_799129] 
 5Trial Phase Phase II 
Clinical Indication Malignant peritoneal mesothelioma 
Trial Type Treatment 
Type of control None 
Route of administration Intravenous 
Trial Blinding None 
Treatment Groups  1 
Number of trial subjects 37 subjects 
Estimated enrollment period 24 months 
Estimated duration of trial 42 months 
Duration of Participation  18 months 
 
 
 
 1.0 TRIAL DESIGN 
1.1 Trial Design  
This is a single institution, singl e-arm, phase II trial of perioper ative combinati on immunotherapy 
(nivolumab + ipi[INVESTIGATOR_125]) in patients with rese ctable malignant peritoneal mesothelioma. All 
patients will undergo pretreatment cross-sectional imaging (CT or MRI) for clinical staging, as 
well as a laparoscopy to stage the peritoneum, asse ss resectability, and acquire pretreatment tissue, 
all of which is part of standard of care. Enrolled  patients will then receiv e neoadjuvant combination 
immunotherapy, which will include 2 doses of nivol umab (3 mg/kg IV every 21 days) and 1 cycle 
of ipi[INVESTIGATOR_125] (1 mg/kg IV ). Repeat cross-se ctional imaging (CT or MR I) will be performed to 
assess response to neoadjuvant immunotherapy. Su rgical intervention via cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemope rfusion (HIPEC) with mitomycin-C will occur 2-
[ADDRESS_1102179] dose of  the neoadjuvant therapy, at wh ich point additio nal pathologic 
assessments will be made. About 6-8 weeks following surgery and after new baseline cross-sectional imaging is completed, patients will re ceive adjuvant ipi[INVESTIGATOR_162] b (2 cycles; 1mg/kg IV 
every 6 weeks) + nivolumab (1 year). Restaging cross sectional scans will be obtained to assess 
response every 6 weeks while on adj uvant therapy and every 3 months for an additional year after 
completing therapy.  
The primary objective of the study is to assess the rate of majo r pathologic response (MPR), 
defined as 10% residual viable tumor (RVT) in th e resected surgical specimen following 
neoadjuvant nivolumab + ipi[INVESTIGATOR_43839]. Secondary objectives include  assessment of  the safety 
profile and feasibility of the neoadjuvant regimen, radiologic re sponse rate, and overall and 
progression-free survival. Samples will be obtained pretreatment via laparoscopy and after nivolumab + ipi[INVESTIGATOR_799130]. Additio nal correlatives will be assessed 
including immune status/infiltration of the tumo r, CA-125 serum levels, serum SRMP (soluble 
mesothelin-related peptide), circulating tumo r cells, as well as ra diologic correlatives. 
 
 61.2 Trial Schema 
 
 
2.0 OBJECTIVES 
2.1 Primary Objectives 
1. To determine pathologic re sponse of the tumor to ne oadjuvant treatment with 
nivolumab + ipi[INVESTIGATOR_799131] a Major Pathologic Response (MPR), defined as ≤10% 
residual viable tumor (RVT) cells, as  well as grade, necrosis, and Ki67. 
2.2 Secondary Objectives  
1. To determine the safety pr ofile of neoadjuvant nivolum ab + ipi[INVESTIGATOR_125], as defined 
by [CONTACT_799159]/IV adverse events according to CTCAE v5.0, occurring up to [ADDRESS_1102180]-operatively.  
2. To determine feasibility of neoadjuvant ni volumab + ipi[INVESTIGATOR_125], as measured by [CONTACT_799160] + 
ipi[INVESTIGATOR_799132]-related delay (> 6-
week delay) or progre ssion precluding surgery.  
 
3. To determine the Overall Survival (OS)  effect from neoadjuvant nivolumab + 
ipi[INVESTIGATOR_125], defined as time from enrollment on study to de ath from any cause.   
 
4. To determine the Progression-free Survival (PFS) effect from ne oadjuvant nivolumab 
+ ipi[INVESTIGATOR_125], defined as tim e from enrollment on study to disease progression or 
death.  
 Malignant  
Peritoneal  
Mesothelioma
All histologies
18 yrs
ECOG < 2
No IO/chemo  within 4 
weeks
EXCLUSION:
Not a candidate  for 
CRS/HIPEC
Visceral metastasesBaseline 
imaging, labs
Staging 
laparoscopy  
and biopsyE
N
R
O
L
L
M
E
N
TNeoadjuvant  
IO
Nivolumab  IV 
3mg/kg Q3wks x2 + 
Ipi[INVESTIGATOR_125]  1mg/kg 
Q6wks x1
Restaging
Radiologic  
reassessment  after 
Nivo x2 and Ipi x1Restaging  
Radiologic  
assessment  (ORR by 
[CONTACT_393] 1.1)
CRS/HIPEC
Pathologic  
assessment  (MPR, 
grade, necrosis, 
Ki67, immune 
infiltrate)Adjuvant 
IO
Nivolumab  IV 
3mg/kg Q3wks 
x1yr + 
Ipi[INVESTIGATOR_125]  
1mg/kg Q6wks
x2 cyclesFollow‐up
H&P, Labs, 
Imaging Q3mo 
x1 yr
 75. To determine the safety profile of ad juvant nivolumab + ipi[INVESTIGATOR_799133].  
 
6. To determine the radiologic response to neoadjuvant nivolumab + ipi[INVESTIGATOR_799134] 1.[ADDRESS_1102181] of  neoadjuvant nivolumab + ipi[INVESTIGATOR_799135] (PCI).  
 
2.3 Exploratory Objectives 
1. To determine immune status /infiltration of the tumor in  response to neoadjuvant 
nivolumab + ipi[INVESTIGATOR_125], incl uding the change in pres ence of TILs/macrophages 
(CD3, CD4, CD8, CD11b, CD68, CD 20) and PDL1 status.  
 
2. To determine blood-based changes with nivolumab + ipi[INVESTIGATOR_45777], 
including PBMC inflammation expressi on profile, serum mesothelin (SMRP), 
osteopontin, CA-125, and circulating tumor cells. 
 
3. To evaluate health-related quality of life (HRQoL) for patients with peritoneal 
mesothelioma undergoing perioperative immunotherapy, measured by [CONTACT_70128] C30, which was developed specifically to assess quality of life in patients with 
cancer.  
 
4. To correlate radiologic tu mor measurements based on RECIST 1.[ADDRESS_1102182] immune surveillan ce in controlling outgrowth of neoplastic 
transformation has been known for decades.  Ac cumulating evidence shows a correlation between 
tumor-infiltrating lymphocytes (TILs) in can cer tissue and favorable  prognosis in various 
malignancies.  In particular, the presence of CD8+ T-cells and the ra tio of CD8+ effector T-cells / 
FoxP3+ regulatory T-cells seems to correlate with improved prognos is and long-term survival in 
many solid tumors (Facciabene, 2012).  
The PD-[ADDRESS_1102183] hijacked by [CONTACT_13207].  The normal function of  PD-1, expressed on the cell su rface of activated T-cells under 
 8healthy conditions, is to down-regulate unwanted or excessive immune respons es.  PD-1 is an Ig 
superfamily member related to CD28 and CTLA-4 that has been shown to negatively regulate 
antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2).   
PD-1 was shown to be expressed on activated ly mphocytes including periph eral CD4+ and CD8+ 
T-cells, B-cells, T regs and Natural Killer cells.  Expression has also been shown during thymic 
development on CD4-CD8- (double negative) T-cells as well as  subsets of macrophages and 
dendritic cells.  The ligands for PD-1 are constitutively expressed or  can be induced in a variety of 
cell types, including non-hematopoieti c tissues as well as in various tumors.  Binding of either PD-
1 ligand to PD-1 inhibits T-cell activation triggered th rough the T-cell receptor.   
Although healthy organs express litt le (if any) PD-L1, a variety of cancers were demonstrated to 
express abundant levels of this  T-cell inhibitor.  PD -1 has been suggested  to regulate tumor-
specific T-cell expansion in subj ects with melanoma, consistent with the understa nding that the 
PD-1/PD-L1 pathway plays a critical role in tumo r immune evasion and ther eby [CONTACT_799161]. 
Nivolumab is a potent human i mmunoglobulin G4 (IgG4) monocl onal antibody (mAb) that binds 
to the PD-[ADDRESS_1102184] ivity. Ipi[INVESTIGATOR_142] a monoclona l antibody that binds to CTLA-
4 and blocks the interaction of  CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has 
been shown to augment T-cel l activation and proliferati on, including the activation and 
proliferation of tumor infiltra ting T-effector cells. Inhibiti on of CTLA-4 signaling can also 
reduce T-regulatory cell function, which may contribute to a general increase in T cell 
responsiveness, including the anti-tumor immune response. 
 
Combined nivolumab (anti-PD-1) and ipi[INVESTIGATOR_125] (anti-CTLA-4) mediated inhibition has also 
been shown to result in enhanced T-cell function that is greater th an the effects of either antibody 
alone, suggesting a synergistic effect of the co mbination, and results in  improved anti-tumor 
responses in metastatic melano ma and advanced RCC. In murine  syngeneic tumor models, dual 
blockade of PD-1 and CTLA-4 resulted in increased anti-tumor activity (Fiegle, 2019). 
 
3.[ADDRESS_1102185] Populations 
Around 500-800 new cases of peritoneal mesothelio ma occur every year in the [LOCATION_002] 
(Miura, 2014). In contrast to pleural mesothelio ma, an antecedent exposu re to asbestos cannot 
always be found in patients with this disease. Ho wever, we previously demonstrated that germline 
mutations (with BAP1  mutations being most common) are f ound in as many as 25% of peritoneal 
mesothelioma patients, compared  to only 7% of those with pl eural disease (Panou, 2018), implying 
that inherited susceptibility may play a larger role  in peritoneal mesothelioma. Patients generally 
present with ascites or malignant  bowel obstructions, which are sign ificantly life limiting due to 
the resulting malnutrition and inanition. Cross s ectional imaging such as CT scans or MRIs are 
 9utilized in the diagnosis of pe ritoneal mesothelioma but they generally unde restimate the burden 
of disease. There are 3 major histologic subtypes  of mesothelioma: epi[INVESTIGATOR_018], sarcomatoid, and 
mixed or biphasic (Husain, 2009).  Pathologic subtype is one of  the most important prognostic 
indicators in this disease, so  an accurate determination of pa thology is essential (Rusch, 2012).  
The prognosis of patients with pe ritoneal mesothelioma  is rather dismal in the absence of 
treatment, with a median surviv al of 12 months (Alexander, 2013). The standard of care for 
patients with peritoneal mesothelioma is the performance of cytoreductive surgery (CRS) and 
hyperthermic intra-peritoneal ch emotherapy (HIPEC). The surger y consists of extirpation of 
peritoneal tumor with parietal and visceral per itonectomy procedures and visceral resections as 
necessary. During the surgery, th e burden of disease is assessed by [CONTACT_799162] 
(PCI score). This score is meas ured by [CONTACT_799163]  13 zones (including 4 zones for 
the bowel) and ranges from 0-39 ( [ADDRESS_1102186] disease). At  the end of the operation the 
residual tumor is assesse d by [CONTACT_799164]. Heated chemotherapy is then applied to the peritoneal 
surfaces for 90 minutes and circul ated at 600 ml-1500ml/min at 42 0C (Turaga K 2016).  
Patients undergoing CRS+HIPEC have an overall medi an survival of 53 months, with a more 
favorable prognosis for patients that undergo a complete cytoreduction (CC-0/1)(Yan TD 2009). 
The agent of choice for the intra-operativ e chemotherapy is either platinum based 
(cisplatin/carboplatin) or mitomycin C (Helm, 2 015). Grade III-IV complica tion rates after this 
surgery can be as high as 31-40% (Kepenek ian 2016). Major complications include death, 
anastomotic leak, deep or superficial site inf ection, anemia, re-operations , organ failure including 
renal failure, cardiac failure or  respi[INVESTIGATOR_1399], neutrope nia, thromboembolic events, 
dehydration and failure to thrive.  
Due to the relatively low incidence of perito neal mesothelioma, ther e are no large randomized 
controlled trials for either surgery or chem otherapy to guide management, leaving no clear 
consensus on optimal treatment approach. Therefor e, much of the management is extrapolated 
from the studies in pleural mesothelioma. Standard chemotherapy for pleural mesothelioma consists of pemetrexed plus cisplatin.  This regimen was FDA-approved for MM based on a single-
blind, placebo-controlled, phase I II trial, which randomized 456 pati ents to cisplatin with or 
without pemetrexed. Patients wh o received the combination ach ieved a longer median overall 
survival (12.1 vs. 9.3 months, p = 0.020), a superior time to pr ogression (5.7 vs. 3.9 months, 
p = 0.001), and a higher objective re sponse rate (41% vs. 17%, p < 0.001) than patients who 
received cisplatin alone (Vogelzang, 2003).   However, the benefits of cytotoxic chemotherapy for peritoneal mesothelioma are less clear and 
alternative therapi[INVESTIGATOR_799136]. PD-1/PD-L1 and CTLA4 are 
immune checkpoints that mediate immune evasion in  a wide spectrum of tumors. While the normal 
function of PD-[ADDRESS_1102187] became 
evident with the promising results of clinical trials of PD-1/PD-L1  and CTLA4 inhibitors, such as 
pembrolizumab (Hamid, 2013), nivolumab (Wolchok, 2013), and MPDL3280A (Powderly, 2013). 
While immune checkpoint blockers have not been evaluated in me sothelioma in the neoadjuvant 
setting, they are being used safe ly in the preoperative setting in a variety of tumor types. 
 10In an analysis presented at ASCO 2014 (Kindler , 2014), we analyzed gene expression data on 44 
malignant mesothelioma tumors (Gordon, 2005), a pplied a melanoma-derive d signature [CONTACT_4007] T-cell 
inflammation (Harlin, 2009), and analyzed other immune response related genes. We identified 
that 32% of malignant mesotheliomas showed hi gh CD8 gene expression, and a T-cell inflamed 
phenotype analogous to melanomas wa s present in multiple tumors. 
 We evaluated MM tumor tissues  from patients by [CONTACT_7163]-color  immunohistochemistry (IHC), 
staining for CD68 (macrophages), CD8 (tumor infiltrating lym phocytes), and PD-L1 (immune 
checkpoint, MTA: Liepi[INVESTIGATOR_15125]) We obser ved PD-L1 expression in 75% of MM  tumors tested, 
which was 2-3+ in 37.5%, and 1+ in 37.5%. Pa tchy higher level PD-L1 expression was observed 
in stromal or CD68 cells located close to CD8+ cells. CD8 tumor infiltrating lymphocytes (TILs) 
were present in all epi[INVESTIGATOR_220]. Prominen t CD68 infiltration was seen in all tumors.  
Thus, we identified high PDL- 1 expression, a CD8 infiltrative pa ttern with a T-cell inflamed 
expression, and presence of PD-1/PD-L1 immune checkpoints in a subset  of MM (approximately 
1/3 of MM tumors) similar to the phenotype found in  other tumors such as melanoma that benefit 
from immune checkpoint blockade.  Furthermore, we recently identified a marked heterogeneity 
in PD-L1 expression speci fically in peritoneal mesothelioma a ssociated with either systemic or 
intraperitoneal chemothe rapy administration (White , 2020). This demonstrates  the pliability of 
PD-L1 as a biomarker, indicating th at a low PD-L1 status at a singl e timepoint should not preclude 
patients from immune chec kpoint inhibition therapy. 
 Based on these and other studies, MM is an ideal ta rget disease for anti-PD-1 therapy, and further 
investigation of the biology of th is agent in this disease is wa rranted. This hypothesis is further 
supported by [CONTACT_799165] e CheckMate 743 study. This was a randomized, 
open-label trial in patients with unresectable malignant pleural mesothelioma, with a primary 
endpoint of overall survival. Patients were randomized to receive either combination 
immunotherapy with nivolumab + ipi[INVESTIGATOR_344670] [ADDRESS_1102188] chemotherapy with 
pemetrexed + either cisplatin or  carboplatin for [ADDRESS_1102189] line 
therapy. (Baas 2020).  Therefore, we expect to see a si milar response to imm unotherapy in the periton eal disease setting, 
and with this study we aim to evaluate that respon se. Of note, while resection is typi[INVESTIGATOR_799137]-sarcomat oid histology, in this trial we  plan to include sarcomatoid 
histologies as well. Due to the robust response in the CheckMate  [ADDRESS_1102190] a similar response, making 
their disease more amen able to cytoreduction.  
 
3.2.2 
Rationale for Endpoints 
Tumor response is a surrogate mark er of benefit from immune ther api[INVESTIGATOR_799138], ipi[INVESTIGATOR_43844], and other immune therapie s. Response is considered a 
reliable marker of benefit for malignant mesothelioma and correlates with a survival benefit 
 11(Blayney, 2012). Response in pleural mesothelio ma is generally assessed via the modified 
RECIST 1.1 criteria for assessm ent of response in mesothelioma (Armat o 2018).  However, 
radiologic assessments of tumor response in per itoneal disease are poor and usually underestimate 
the burden of disease. 
Retrospective analyses have re vealed that Ma jor Pathologic Response (M PR) after neoadjuvant 
chemotherapy was related to improved overall survival and disease-free survival. Chaft et 
al. examined neoadjuvant chemotherapy for non -squamous NSCLC (non-sm all cell lung cancer) 
and reported that 22% of tumors showed MPR, w ith these responses being associated with long-
term survival. Furthermore, MPR has since been  used in several pros pective and randomized 
studies and has now been recomm ended as a surrogate endpoint sp ecifically in th e context of 
neoadjuvant immunotherapy (Hellmann, 2014). Pa thologic responses, such as MPR and 
pathologic complete response are to date the most commonly used metrics for assessing response 
to neoadjuvant immunotherapy, and have been used in trials for melanoma , colon cancer, NSCLC, 
muscle-invasive bladder cancer, and several ot hers (Chalabi, 2020; Yang, 2020). Patients with 
non-small cell lung cancer who rece ived neoadjuvant nivolumab were found to have a 45% rate 
of MPR (Bott, 2019), and 30% of those with res ectable stage III/IV mela noma who received just 
a single dose of pembrolizumab had MPR, 100% of which had a durable disease-free survival at 
24 months (Huang, 2019). This pa thologic response is seen not only in those with known 
susceptibility to immunotherapy, such as those with mismatch repair deficient (dMMR) tumors. 
In the NICHE study, though colorect al cancer patients with dMMR  tumors had a 95% MPR rate, 
those with MMR-proficient tumors still had a robust res ponse with 20% MPR rate  (Chalabi, 2020).  
 4.[ADDRESS_1102191] 18 years of  age, of any ethnic  or racial background, 
are included. Children ( ≤18 years of age) will be excluded from this study to limit variability in 
the study population and avoid this vulnerable popul ation. There is no restriction on the racial or 
ethnic origin of subjects. Please see the inclus ion and exclusion criteria for full details. 
Prospective approval of protocol deviations to recruitment and en rollment criteria,  also known as 
protocol waivers or exem ptions, is not permitted. 
4.[ADDRESS_1102192]: 
1. Have a diagnosis of histologically or cytologi cally confirmed periton eal mesothelioma, of 
epi[INVESTIGATOR_018], biphasic, or  sarcomatoid subtypes 
 
2. Have disease burden amenable to cytore duction and hyperthermic intraperitoneal 
chemotherapy (HIPEC), as de termined by a surgeon special izing in mesothelioma  
 [ADDRESS_1102193] staging 
 
5. Be willing to undergo laparoscopy or mini- laparotomy for peritoneal staging 
 
6. Demonstrate adequate organ f unction as determined by [CONTACT_799166], with criteria 
defined in Table 1 
 Table 1.  Adequate Organ Func tion Laboratory Values 
System Laboratory Value 
Hematological   
Absolute neutrophil count (ANC) ≥ 1,500 /L 
Platelets ≥ 100,000 / L 
Hemoglobin ≥ 9 g/dL  
Renal  
Serum creatinine OR 
Measured or calculateda 
creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤ 1.5 X upper limit of normal (ULN) OR 
 
≥ 60 mL/min for subject with creatinine levels > 
1.[ADDRESS_1102194] 
Hepatic  
Serum total bilirubin ≤ 1.[ADDRESS_1102195] (SGOT) and ALT (SGPT) ≤ 2.[ADDRESS_1102196]   
Coagulation 
International Normalized Ratio 
(INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT)  
≤ 1.[ADDRESS_1102197] an ECOG performance status of < 2 
 
8. Be  [ADDRESS_1102198]:  
1. Is currently participating in a study of an  investigational agent and received an 
investigational agent within [ADDRESS_1102199] 
dose of treatment on this protocol  
 133. Has a diagnosis of immunodeficien cy or is receiving chronic systemic steroid therapy (>10 
mg of prednisone daily or equivalent) or any other form  of immunosuppressive therapy 
within [ADDRESS_1102200] dose of study drug.  
4. Has a known history of active TB infection (Bacillus tuberculosis) 
 
5. Has active COVID-[ADDRESS_1102201] 2 years 
(i.e. with use of disease m odifying agents, corticosteroid s or immunosuppressive drugs) 
 
10. Has a known additional malignancy that is prog ressing or required active treatment within 
the [ADDRESS_1102202] dose of study medication (R eference Section 5.8.2).  Subjects of 
childbearing potential are those who ha ve not been surgically sterilized 
or have not been free from  menses for > [ADDRESS_1102203] Identification & Recruitment  
Patients will be identified duri ng the initial medical oncology or surgical oncology appointment. 
Patients will be screened for the appropriate inclus ion and exclusion criteria and recruited to the 
trial as appropriate. There will be no use of advertisements, bu t it will be listed on the Cancer 
Center website. Patients will not be id entified through medical records.  
4.[ADDRESS_1102204] be collected through th e participant’s last scheduled fo llow up, even if the participant 
has discontinued study intervention. Therefore, all participants who discontinue study intervention 
prior to completion of the protocol-specified treatme nt period will still continue to participate in 
the study.  Participants may discontinue study intervention at  any time for any reason or be discontinued from 
the study intervention at the discretio n of the investigator should a ny untoward effect occur. Also, 
a participant may be discontinued from study inte rvention by [CONTACT_799167], the study plan is violated, or  for administrative and/or  other safety reasons. 
A participant must be discontinue d from study intervention but cont inue to be monitored in the 
study for any of the fo llowing reasons:  
1. The participant or participan t’s legally acceptable representa tive requests to discontinue 
study intervention.  
2. Any occurrence of another maligna ncy that requires treatment.  
3. Unacceptable AEs or toxicities  
4. The participant interrupts st udy intervention administration for >[ADDRESS_1102205] be withdraw n from the study if the particip ant or participant’s legally 
acceptable representative withdraws consent from the study. If a particip ant withdraws from the 
study, they will no longer receive st udy intervention or be followed at scheduled protocol visits.  
Lost to Follow-up 
If a participant fails to retu rn to the clinic for a required study vi sit and/or if the site is unable to 
contact [CONTACT_2299], the following procedures are to be performed:  
1. The site must attempt to contact [CONTACT_799168]. If the 
participant is contact[INVESTIGATOR_530], th e participant should be counseled on the importance of 
maintaining the protocol-sp ecified visit schedule.  
2. The investigator must make every effort to regain contact [CONTACT_190365] e participant at each 
missed visit (e.g. telephone  calls and/or a certified letter  to the participant’s last known 
mailing address or locally equivalent me thods). These contact [CONTACT_799169]’s medical record.  
3. Note: A participant is not considered lost to follow-up until the last scheduled visit for the 
individual participant. The missing data fo r the participant will be managed via the 
prespecified statistical data ha ndling and analysis guidelines.  
5.[ADDRESS_1102206] to determin e extent of disease. They will also undergo a 
laparoscopy or mini-laparotomy for peritoneal  carcinomatosis index (PCI) staging and pre-
treatment tissue biopsy. The la paroscopic surgery is  performed under gene ral anesthesia, and 
involves inserting a [ADDRESS_1102207] of care for patients 
with peritoneal mesothelioma w ho are considered for CRS/HIPEC. 
 
5.2 Neoadjuvant Nivolumab and Ipi[INVESTIGATOR_125] 
5.2.1 Drug Supply 
Both nivolumab and ipi[INVESTIGATOR_799139].  
 
5.2.2 Dose Selection 
Neoadjuvant nivolumab is deliver ed at a dose of 3 mg/kg over 30 minutes every 21 days via IV 
infusion on day 1 and day 22 of each 42-day cycle for 2 doses (1 cycle). 
 16Neoadjuvant ipi[INVESTIGATOR_799140] a dose of 1 mg /kg over 30 minutes ev ery 42 days via IV 
infusion on day 1 of each 42-day cycle for 1 dos e (1 cycle). When given on the same day as 
nivolumab, ipi[INVESTIGATOR_799141].  
 
5.2.3 Dose Modification 
Adverse events (both non-serious and serious) as sociated with nivolumab or ipi[INVESTIGATOR_799142]. These adverse events may occur shortly after the first 
dose or several months after the last dose of treatment. No dose reduc tion for nivolumab or 
ipi[INVESTIGATOR_799143] d. In general, withhold nivolumab and ipi[INVESTIGATOR_799144] (Grade 
3) immune-mediated adverse reactions. Permanently discontinue the agents for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated 
reactions that require  systemic immunosuppressive treatme nt, or an inab ility to reduce 
corticosteroid dose to 10 mg or less of predni sone or equivalent per day within 12 weeks of 
initiating steroids.   Dosage modifications for nivolum ab or ipi[INVESTIGATOR_799145] (Appendix).  Dosing interruptions are permitted in  the case of medical / surgical events or logistical reasons not 
related to study therapy (e.g., elect ive surgery, unrelated medical ev ents, patient vacation, and/or 
holidays). Subjects should be placed back on st udy therapy within 3 we eks of the scheduled 
interruption, unless otherwise disc ussed with the Principal Investigator. The reason for interruption 
should be documented in the patient's study record. 
 
5.[ADDRESS_1102208] dose of 
nivolumab, to achieve an adequate cytoreduction of all residual gross tumor. CRS+HIPEC, which 
can be performed via a laparoscopic or an open laparotomy approach, incl udes but is not limited 
to peritonectomy procedures wher eby [CONTACT_799170], omentectomy and other 
visceral resections as necessary to reduce th e tumor burden to minimal residual disease. 
Completeness of cytoreduction and PCI scores w ill be documented. The dose of intraperitoneal 
chemotherapy will be [ADDRESS_1102209] 2 cycles in the adjuvant phase will incl ude nivolumab delivered at a dose of 3 mg/kg over 
30 minutes every 21 days via IV infusion on day 1 and day 22 of each 42-day cycle for 4 doses (2 
cycles) and ipi[INVESTIGATOR_799146] a dose of 1 mg/kg over 30 minutes every 42 days via IV 
infusion on day 22 of each 42-day cycle for 2 doses (2 cycles). When given on the same day as 
nivolumab, ipi[INVESTIGATOR_799147]. Following these first [ADDRESS_1102210]-operatively.   
6.0 ADDITIONAL METHODOLOGY 
6.1 Trial Blinding/Masking 
This is an open-label trial; therefore, the i nvestigator and subject will know the treatment 
administered. 
6.2 Randomization or Treatment Allocation  
There will be no randomization. All patients that m eet criteria will be enro lled in the single arm. 
6.3 Stratification  
No stratification will be done.  
6.4 Concomitant Medications/Vaccinations (allowed & prohibited)  
Medications or vaccinations speci fically prohibited in the exclusi on criteria are not allowed during 
the ongoing trial.  If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or 
vaccination may be required. The final decision on any supportive therapy or vaccination rests 
with the investigator and/or the subject's pr imary physician.  
 
6.4.[ADDRESS_1102211]’s welfare may be 
administered at the discretion of the treating inves tigator in keepi[INVESTIGATOR_133594].  All concomit ant medication will be recorded on the case report form (CRF) 
including all prescription, over- the-counter (OTC), herbal suppl ements, and IV medications and 
fluids.  If changes occur during the trial period, docume ntation of drug dosage, frequency, route, 
and date may also be included on the CRF. 
 18All concomitant medications received within [ADDRESS_1102212] dose of trial tr eatment should be recorded as well. 
6.4.2 Prohibited Concomitant Medications 
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_478445]: 
 Immunotherapy not specif ied in this protocol 
 Chemotherapy not specifie d in this protocol 
 Investigational agents not specified in this protocol 
 Radiation therapy   
 Live vaccines within [ADDRESS_1102213] dose of trial treatment and while participating 
in the trial.  Examples of live vaccines in clude, but are not limite d to, the following: 
measles, mumps, rubella, vari cella/zoster, yellow fever, ra bies, BCG, and typhoid vaccine.  
 Systemic glucocorticoids while on nivolumab and ipi[INVESTIGATOR_251430] a ny purpose other than 
to modulate symptoms from an event of cl inical interest of suspected immunologic 
etiology.  The use of physiologic doses of  corticosteroids may be approved after 
consultation with the Principal Investigator. 
Subjects who, in the assessment by [CONTACT_12707], re quire the use of any of the 
aforementioned treatments for clin ical management should be rem oved from the trial.  Subjects 
may receive other medications th at the treating investigator d eems to be medically necessary. 
The Exclusion Criteria describes other medica tions that are prohibited in this trial. 
There are no prohibited therapi[INVESTIGATOR_110504]-Treatment Follow-up Phase. 
6.5 Supportive Care Guidelines 
Subjects should receive appropriate  supportive care measures as de emed necessary by [CONTACT_124133].  Suggested supporti ve care measures for the management of ad verse events with 
potential immunologic etiology are outlined below.  Where appropriate, these guidelines include 
the use of oral or intravenous treatment with cor ticosteroids as well as a dditional anti-inflammatory 
agents if symptoms do not improve with administr ation of corticosteroids.  Note that several 
courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is 
decreased. For each disorder, attempts should be made  to rule out other caus es such as metastatic 
disease or bacterial or viral infection, which might require additional supportive care. The 
treatment guidelines are intended to be applied when  the treating investigator determines the events 
to be related to the study treatment.  
It may be necessary to perform conditional pro cedures such as bronchoscopy, endoscopy, or skin 
photography as part of ev aluation of the event.  
 19 Pneumonitis :  
o For Grade 2 events , treat with systemic corticoste roids. When symptoms improve 
to Grade 1 or less, steroid taper should be started and contin ued over no less than 4 
weeks. 
o For Grade 3-4 events , immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory  measures, as needed. 
o Add prophylactic antibiotics for opportunistic  infections in the case of prolonged 
steroid administration. 
 Diarrhea/Colitis :  
Subjects should be carefully mon itored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in  stool, with or without fever) an d of bowel perforation (such as 
peritoneal signs and ileus).   
o All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake  is not feasible, fluid and 
electrolytes should be substituted via IV in fusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis. 
o For Grade 2 diarrhea/colitis  that persists greater than 3 days, administer oral 
corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis  that persists > 1 wee k, treat with intravenous 
steroids followed by [CONTACT_78018].   
o When symptoms improve to Grade 1 or le ss, steroid taper should be started and 
continued over no less than 4 weeks. 
 Type 1 diabetes mellitus (if new onset, in cluding diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 Hyperglycemia, if asso ciated with ketosis (ketonuria) or metabolic acidosis 
(DKA) 
o For T1DM  or Grade 3-4  Hyperglycemia 
 Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3-4 hyperglycemia associ ated with metabolic acidosis or 
ketonuria.  
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglob in, and C-peptide.  
 Hypophysitis : 
 20o For Grade 2  events, treat with corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered. 
o For Grade 3-4  events, treat with an initial dose of IV corticosteroids followed by 
[CONTACT_78019]. When symptoms im prove to Grade 1 or less, steroid taper 
should be started and con tinued over no less than 4 weeks. Replacement of 
appropriate hormones may be required  as the steroid dose is tapered. 
 Hyperthyroidism or Hypothyroidism :  
Thyroid disorders can occur at an y time during treatment. Monitor pa tients for changes in thyroid 
function (at the start of treatment , periodically during treatment, a nd as indicated based on clinical 
evaluation) and for clini cal signs and symptoms of thyroid disorders. 
o Grade 2  hyperthyroidism events (and Grade 2-4  hypothyroidism): 
 In hyperthyroidism, non- selective beta-blocker s (e.g. propranolol) are 
suggested as initial therapy. 
 In hypothyroidism, thyroid horm one replacement therapy, with 
levothyroxine or liothyr oinine, is indicated per standard of care. 
o Grade 3-4  hyperthyroidism  
 Treat with an initial dose of IV corticosteroid followed by [CONTACT_79918]. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  Replacement of 
appropriate hormones may be required  as the steroid dose is tapered. 
 Hepatic : 
o For Grade 2  events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly). 
 Treat with IV or oral corticosteroids 
o For Grade 3-4  events, treat with intravenous co rticosteroids for 24 to 48 hours.  
o When symptoms improve to Grade 1 or le ss, a steroid taper should be started and 
continued over no less than 4 weeks. 
 Renal Failure or Nephritis : 
o For Grade [ADDRESS_1102214] emic corticosteroids. 
 21o When symptoms improve to Grade 1 or le ss, steroid taper should be started and 
continued over no less than 4 weeks.  
Management of Infusion Reactions : 
Discontinue nivolumab and ipi[INVESTIGATOR_799148] (Grade 3) or life-threatening 
(Grade 4) infusion-related reactions. Interrupt or sl ow the rate of infusion in patients with mild 
(Grade 1) or moderate (Grade 2) infusion-rela ted reactions.  
6.6 Diet/Activity/Other Considerations 
6.6.[ADDRESS_1102215]-feeding wo men may be enrolled if they ar e willing to us e 2 methods of 
birth control or are considered hi ghly unlikely to conceive.  Highly unlikely to conceive is defined 
as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥ 45 years of age and has not 
had menses for greater than 1 ye ar will be considered postmenopausal), or 3) not heterosexually 
active for the duration of the st udy.  The two birth control methods  can be either two barrier 
methods or a barrier method plus  a hormonal method to prevent pr egnancy. Subjects should start 
using birth control from study Vis it [ADDRESS_1102216] dose 
of study therapy.   The following are considered adequate barrier me thods of contraception:  diaphragm, condom (by 
[CONTACT_3969]), copper intrauterine device, sp onge, or spermicide.  Appropriate hormonal 
contraceptives will include any registered and ma rketed contraceptive agent that contains an 
estrogen and/or a progesterone agen t (including oral, subcutaneous, intrauterine, or intramuscular 
agents).  Subjects should be informed th at taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur dur ing the study.  In order to participate in the 
study, they must adhere to the contraception requir ement (described above) for the duration of the 
study and during the follow-up peri od. If there is any question that  a subject will not reliably 
comply with the requirements fo r contraception, that subject shoul d not be entered into the study. 
 
6.6.[ADDRESS_1102217] will immediately be 
removed from the study.  The treating investigator a nd/or their designee will contact [CONTACT_358637]’s status until the pre gnancy has been completed or 
terminated.  The outcome of the pregnancy will be reported to the Principal Investigator. 
 22If a male subject impregnates his female partner the study personnel at  the site must be informed 
immediately and the pregnancy reported to the Pr incipal Investigator and followed as described 
above.  
6.6.[ADDRESS_1102218] Withdrawal/Discontinuation Criteria 
Subjects may withdraw consent at  any time for any reason or be dropped from the trial at the 
discretion of the principal and/or  treating investigator should a ny untoward effect occur.  In 
addition, a subject may be withdraw n by [CONTACT_618909]/or treati ng investigator if enrollment 
into the trial is inappropriate, the trial plan is violated, or for administra tive and/or other safety 
reasons.  Further details ar e described in Section 4.7. 
 
6.8 Clinical Criteria for Early Trial Termination 
Early trial termination will be the result of the criteria specified below: 
1. Quality or quantity of data recording is inaccurate or incomplete 
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or severity of adverse drug reaction in this or other studi es indicates a potential health 
hazard to subjects 
4. Plans to modify or discontinue the development of the study drug 
5. If [ADDRESS_1102219] and surgeon.  
6. Assuming a major complication rate of 10% fr om the combination immunotherapy (Taioli, 
2015), the trial will be halted if any major complication which is attributed to the 
investigational drug occurs in th e first two patients, or in [ADDRESS_1102220] and su rgeon. A composite adverse ev ent of major complications 
defined as the occurrence of any ventricula r arrhythmia requiring treatment, hemorrhage 
requiring re-operation, acute resp iratory distress syndrome (ARD S), pneumonia, reintubation, 
placement of a tracheostomy, pu lmonary embolus, empyema, seps is, intra-abdominal sepsis, 
myocardial infarction and unexpected return  to the operating room will be monitored 
sequentially.  
 237.0 TRIAL PROCEDURES 
7.1 Flow Chart – Schedule of Events 
7.1.1 Flow Chart for Screening, Neoadjuvant, and Surgery Phases 
Table 2.  Trial Flow Chart of Screening, Neoadjuvant, and Surgery Phases 
 24 
 Trial Phase: Screening 
Phase Neoadjuvant Treatment Phase Pre-Surgery 
Phase Surgery Phase Post-Surgery 
Recovery Phase 
 Screening 
(Visit 1) C1 D1 C1 D22C 4 Weeks 3 Weeks 3-4 Weeks 
Scheduling Window (Days): -28 to -1  ± 3    
Administrative Procedures 
Informed Consent X      
Inclusion/Exclusion Criteria X   X X  
Demographics and Medical 
History X   X X  
Prior and Concomitant 
Medication Review X X X X X  
Interventions 
Nivolumab Administration  X X    
Ipi[INVESTIGATOR_799149]  X     
Surgery     X  
Clinical Procedures/Assessments 
Review Adverse Events X X X X   
Full Physical Examination X X X X X  
Height X      
Vital Signs and Weight X X X X X  
ECOG Performance Status X X X X X  
EORTC QOL C30 X   X  X 
Surgeon Assessment X   X   
Medical Oncology Assessment X X X X   
Laboratory Procedures/Assessments: analysis performed by [CONTACT_657264] a 
Pregnancy Test – Urine or Serum 
-HCG X      
CBC with Differential  X X X X   
Comprehensive Serum Chemistry 
Panel X X X X   
INR, PTT X   X   
Urinalysis X      
TSH (reflex T3, T4 if abnormal) X X  X   
Efficacy Measurements b 
Tumor Imaging with CT/MRI X   X   
CA-125 X   X   
Circulating tumor cells X   X   
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood 
Laparoscopy for tissue and PCI 
score assessment X      
Correlative Studies Blood 
Collection c X X  X X  
a. Screening  lab tests to be performed  within [ADDRESS_1102221] dose. After Cycle 1, pre‐dose lab procedures  can be conducted  <[ADDRESS_1102222] scans, scheduling  window is +/‐ [ADDRESS_1102223]-Treatment Phases  
Trial Period: Adjuvant Therapy Phase End of 
Treat-
ment Post-Treatment Phase 
Treatment Week/Title:     Repeat x 1 year 
from surgery Discon Safety 
Follow-
up Follow 
Up 
Visits Survival 
Follow-Up C1 
D1 C1 
D22 C2 
D1 C2 
D22 C1 
D1 C1 
D22 C2 
D1 C2 
D22 
Scheduling Window (Days)c:  ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_1102224]-study anticancer therapy 
status         X     
Survival Status         X X X X 
Review Adverse Events X X X X X X X X X X X X 
Full Physical Examination X X X X X X X X     
Vital Signs and Weight X X X X X X X X     
ECOG Performance Status X X X X X X X X     
EORTC QOL C30 X  X  X  X  X X   
Laboratory Parameters 
CBC with Differential X X X X X X X X     
Comprehensive Serum 
Chemistry Panel X X X X X X X X     
TSH (reflex T3, T4 if 
abnormal) X  X  X  X      
Efficacy Measurement 
Tumor Imaging with CT scan 
every [ADDRESS_1102225] scans, the scheduling  window is +/‐ [ADDRESS_1102226]’s date d signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable 
representative’s dated signature  [INVESTIGATOR_2394] a consent form along with th e dated signature [CONTACT_131029].   A copy of the signed and dated consent form should be  given to the subject before participation in 
the trial.  The initial informed consent form, any subsequent  revised written informed consent form and any 
written information provided to the subject must receive the IRB/E RC’s approval/favorable 
opi[INVESTIGATOR_19349].  The subject or hi s/her legally acceptable re presentative should be 
informed in a timely manner if new information b ecomes available that ma y be relevant to the 
subject’s willingness to continue participation in the trial.  The communication of this information 
will be provided and documented via a revised c onsent form or addendum to the original consent 
form that captures the subject’s dated sign ature or by [CONTACT_423]’s legally acceptable 
representative’s dated signature.  The informed consent will adhere to IRB/ERC requ irements and applicable  laws and regulations. 
 
7.3 Inclusion/Exclusion Criteria Review 
All inclusion and exclusion criteria will be revi ewed by [CONTACT_799171] s ubject qualifies for the trial.  
7.[ADDRESS_1102227] will move 
into survival follow-up.  
7.7 Adverse Event (AE) Monitoring 
The treating  investigator or qualified designee will assess each subject to evaluate for potential 
new or worsening AEs as specified in the Trial Flow Chart and more frequently if clinically indicated.  Adverse experiences will be graded and recorded throughout the study and during the 
follow-up period according to CTCAE (v5.0). Toxiciti es will be characterized  in terms regarding 
seriousness, causality, toxicity grading, and action ta ken with regard to trial treatment.  
7.8 Full Physical Exam 
The treating  investigator or qualified de signee will perform a complete  physical exam during the 
screening period and as indicated in the Trial Flow Chart.  Clinically signi ficant abnormal  findings 
should be recorded as medical history.   
7.9 Vital Signs 
The treating  investigator or qualified designee will take vital signs at screening, prior to the 
administration of each dose of tr ial treatment and at tr eatment discontinuation as specified in the 
Trial Flow Chart. Vital signs should include temp erature, pulse, respi[INVESTIGATOR_697], weight and blood 
pressure.  Height will be measured at screening only. 
 287.10 Eastern Cooperative Oncology Gr oup (ECOG) Performance Scale 
The treating investigator or qua lified designee will asse ss ECOG status at sc reening, prior to the 
administration of each dose of trial treatment and discontinuation of trial treatment as specified in the Trial Flow Chart.   
7.[ADDRESS_1102228] or MRI scans will be obtained at baseline . After completion of neoadjuvant nivolumab + 
ipi[INVESTIGATOR_45777] a CT or MRI imaging will ag ain be repeated after completion of surgery 
(prior to starting adjuvant immunotherapy), and re peated every 6 weeks while on adjuvant therapy 
and every 3 months for 1 year  after completing treatment. 
7.12 Tumor Tissue Collection and Correlative Studies Blood Sampling 
Tumor tissue will be obtained at laparoscopy and at  surgical resection. Correlative studies blood 
sampling for SRMP, osteopontin, CA-125, and circul ating tumor cells will be obtained per Trial 
Flow Chart schedule.    
7.13 Laboratory Procedures/Assessments 
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below Laboratory Safety Evaluati ons (Hematology, Chemistry and Urinalysis) 
Laboratory tests for hematology, chemistry, urinalys is, and others are specified in Table 4.   
Table 4.  Laboratory Tests  
Hematology Chemistry Urinalysis Other 
Hematocrit Albumin Blood Serum β-human 
chorionic 
gonadotropin  (β-hCG)  
† 
Hemoglobin Alkaline phosphatase Glucose PT (INR) 
Platelet count Alanine aminot ransferase (ALT) Protein PTT 
WBC (total and differential) Aspartate amin otransferase (AST) Specific gravity  Total 
thriiodothyronine (T3) 
Red Blood Cell Count Carbon Dioxide (CO 2 or bicarbonate)  Microscopic exam (If abnormal 
results are noted)  Free thyroxine (T4) 
Absolute Neutrophil Count Calcium Urine pregnancy test † Thyroid stimulating 
hormone (TSH) 
Absolute Lymphocyte Count Chloride   Blood for correlative 
studies 
 Glucose   
 Potassium   
 Sodium    
 Total Bilirubin    
 Total protein    
 29Hematology Chemistry Urinalysis Other 
 Blood Urea Nitrogen    
† Perform on women of childbearing potential only. If urine preg nancy results cannot be confirmed as negative, a serum pregnancy  test 
will be required.   
 
Laboratory tests for screening should be perform ed within [ADDRESS_1102229] ed.  Subjects with an 
AE of Grade > [ADDRESS_1102230].  
7.17 Assessing and Recording Adverse Events 
7.17.1  Adverse Event Characteristics  
 CTCAE term (AE description) and grade:  The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 5.[ADDRESS_1102231] access to a copy of the CTCAE version 5.0.  A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/proto colDevelopment/electronic_ applications/ctc.htm 
 
 Attribution  of the AE: 
 30- Definite (5) – The AE is clearly related  to the study treatment. 
- Probable (4) – The AE is likely related to the study treatment. 
- Possible (3) – The AE may be related  to the study treatment. 
- Unlikely (2) – The AE is doubtfully related to the study treatment. 
- Unrelated (1) – The AE is clearly NOT related  to the study treatment.  
 
7.17.2  Adverse Event Definitions 
[IP_ADDRESS]  Adverse Event 
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject ad ministered a pharmaceutical product and which does not necessarily have 
to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for ex ample), symptom, or disease 
temporally associated with the us e of a medicinal product or protocol-specified procedure, whether 
or not considered related to the medicinal product or protocol-speci fied procedure.  Any worsening 
(i.e., any clinically significant adverse change in frequency and/ or intensity) of a preexisting 
condition that is temporally  associated with the use of the study treatment, is  also an ad verse event. 
 Changes resulting from normal growth and developm ent that do not vary significantly in frequency 
or severity from expected levels are not to be considered adverse events.  Examples of this may 
include, but are not limited to, t eething, typi[INVESTIGATOR_799150] a nd children and onset of menses 
or menopause occurring at a phys iologically appropriate time. 
 Adverse events may occur during the course of the use of the study treatment in clinical trials or 
within the follow-up period specifi ed by [CONTACT_760], or prescrib ed in clinical practice, from 
overdose (whether accidental or intenti onal), from abuse and from withdrawal. 
 
Adverse events may also occur in screened subjec ts during any pre-allocati on baseline period as a 
result of a protocol-specified intervention, including wa shout or discontinuati on of usual therapy, 
diet, placebo treatment or a procedure.  Progression of the cancer unde r study is not considered  an adverse event unle ss it is considered to 
be drug related by [CONTACT_12707]. 
 All adverse events will be r ecorded from the time the consent form is signed through 30 days 
following cessation of treatment and at each examination on the Adverse Event case report 
forms/worksheets.   
[IP_ADDRESS]  Serious Adverse Event  
An adverse event is considered serious if it results in ANY 
of the following outcomes:  
1) Death 
2) Life-threatening (e.g. places subjec t at immediate risk of death, this does not include events 
that might have caused death if th ey occurred a greater severity) 
3) Inpatient hospi[INVESTIGATOR_799151] ≥ 24 hours  
 314) A persistent or significant incapacity or subs tantial disruption of the ability to conduct 
normal life functions  
5) A congenital anomaly/birth defect.  
 
[IP_ADDRESS]  Adverse Reactions 
An adverse event is considered to be an adverse reaction if there is evidence to suggest a causal 
relationship to the study agent.  This may in clude a single occurrence of an event strongly 
associated with drug exposure (e.g. Stevens-Jo hnson Syndrome), one or more occurrence of an 
event otherwise uncommon is the study population, or an aggregate analysis of specific events 
occurring at greater th an expected frequency. 
 
7.17.3       Evaluating Adverse Events 
An investigator who is a qualified physician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE ), version 5.0. Any adverse event which 
changes CTCAE grade over the course of a given ep isode will have each change of grade recorded 
on the adverse event case report forms/worksheets.  All adverse events regardless of CTCAE grad e must also be evaluated for seriousness.
 
 
 
 7.17.4  Responsibility for Reporting Adverse Events 
All Adverse Events will be reported to regulat ory authorities, IRB/IECs  and investigators in 
accordance with all applicable global laws and regulations.  
 8.[ADDRESS_1102232] udy is Major Pathologic Response (M PR), defined as presence of 
<=10% residual viable tumor in the resected su rgical specimen. The proportion of patients who 
achieve an MPR will be reported (MPR rate), al ong with an exact 95% confidence interval. 
Sample size considerations: A total of 37 patient s will be enrolled, with the goal to enroll 18-19 
patients per year in 2 consecutive  years. This sample size will  provide 80% power  to detect a 
significant increase in MPR rate of at least 40% using the one-sided binomia l test with the null 
hypothesis H
0:p = 0.[ADDRESS_1102233] the alternative hypothesis H a:p > 0.5 corresponding to an actual MPR 
rate of ~0.[ADDRESS_1102234] and surgeon. Refer to section 6.8 for additional clinical criteria for 
early trial termination.   Analyses to address the secondary objectives will be pr imarily descriptive in nature.  Progression-
free survival (PFS) and overall survival (OS) wi ll be estimated using the Kaplan-Meier method 
with qualitative assessment of th e emergence of a tail at the end of the curve as evidence of long-
term survival, which is not seen in this disease despi[INVESTIGATOR_799152].  Median event times will be determined as the time at which the Kaplan-Meier curve falls below 50%.   
The objective response rate to neoadjuvant ni volumab + ipi[INVESTIGATOR_799153]-sectional 
imaging pre- and post-treatment wi ll be determined along with an exact 90% confidence interval. 
8.3 Exploratory Endpoints 
CD8 tumor infiltrating lymphocytes (TILs) will be assessed by % of tumor showing infiltration 
and calculation of CD8 TIL density in the pre- and post-treatment biopsy specimens. An increase 
in the TIL density will be termed a TIL-response  and correlated with TCIP response using Pearson 
or Spearman rank correlation coefficients.  
Presence of additional patholog ic markers, including CD3, CD4, CD68, and CD20 will be assessed 
in pre- and post-treatment tissue samples. Results will be descriptive and presented in tabular form.  
Changes in PD-L1 expression comp ared between the pre- and pos t-treatment tissue samples will 
be determined using IHC and ma ss spectrometry. Ordinal IHC data  will be assessed using the 
 
 
 
 Wilcoxon signed-rank test. Changes in other con tinuous immune response and biomarker values 
will be analyzed using paired t-tests.    Analysis of variance for repeated measures will be performed to evaluate changes in serum mesothelin and osteopontin  levels over time. 
 9.[ADDRESS_1102235] 
in accordance with the protocol and any applicable laws and regulations. 
 
9.2 Packaging and Labeling Information 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. 
 
9.3 Clinical Supplies Disclosure 
This trial is open-label. Drug identity (nam e, strength) is include d in the label text. 
 
9.[ADDRESS_1102236] parties is  prohibited with the exceptions noted below. Patient confidentiality 
will be ensured by [CONTACT_21654]. Treatment data may be given to the patient’s personal physician or to other appropriate  medical personnel responsible for the patient’s 
welfare. Data generated as a result of the study need to be available fo r inspection on request by 
[CONTACT_23351], the Drug Manufactur er’s representatives, by [CONTACT_799172].  
10.2 Compliance with Financial Disclosure Requirements 
Financial Disclosure requirements are outli ned in the US Food and Drug Administration  
 
 
 
 Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54) and will be 
implemented following institutional standards. 
10.3 Compliance with Law, Audit and Debarment 
The trial will be conducted in an efficient an d diligent manner and in conformance with this 
protocol; generally accepted standards of Good C linical Practice (e.g., Inte rnational Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
Good Clinical Practice: Consolidated Guideline and other ge nerally accepted standards of good 
clinical practice); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical trial. 
10.[ADDRESS_1102237] (FDAMA) and the Food 
and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is  solely responsible 
for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, http://www.clin icaltrials.gov.  Inform ation posted will allow 
subjects to identify potentially appropriate trials for their disease conditions and pursue 
participation by [CONTACT_3379] a central contact [CONTACT_799173] n on appropriate trial 
locations and trial site c ontact information.     
 
10.[ADDRESS_1102238] of the 
clinical trial.   A quality assurance audit/inspection of this study ma y be conducted by [CONTACT_12721]. The 
quality assurance auditor will have access to all medical records, the investigator’s study-related 
files and correspondence, and the informed c onsent documentation of this clinical study. 
The trial will be monitored in the weekly mesothelioma multidisciplinary conference.  
10.6 Data Management 
Data management will be provided via the cancer clinical trial infrastructure available at the 
University of Chicago (eVELOS). It is the responsi bility of the investigator s to record and verify 
the accuracy of subject data.  11.0  REFERENCES 
Alexander HR Jr, Bartlett DL, Pi[INVESTIGATOR_195113], Libutti SK, Royal R, Hughes MS, 
Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated 
with long-term survival after cytoreductive surgery and region al chemotherapy for patients with 
malignant peritoneal mesothelio ma. Surgery. 2013 Jun;153(6):779-86.  
 
 
 
 
 Alley E, Molife LR, Santoro A, et al. Clinical safety and efficacy of  pembrolizumab (MK-3475) 
in patients with malignant pleural mesothelioma (MPM): Preliminary results from KEYNOTE-
028. Proc AACR 2015.  
 
Armato SG, Li P, Husain AN et al. Radiologic -pathologic correlation of mesothelioma tumor 
volume. Lung Cancer. 2015 Mar;87(3):278-82. 
 
Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors 
for Assessment of Response in Malignant Pleu ral Mesothelioma (Versi on 1.1). J Thorac Oncol. 
2018 Jul;13(7):1012-1021.  
 
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, 
Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Corn elissen R, Greillier L, Grossi F, Kowalski D, 
Rodríguez-Cid J, Aanur P, Oukessou A, Baudele t C, Zalcman G. First-line nivolumab plus 
ipi[INVESTIGATOR_799154] e malignant pleural me sothelioma (CheckMate  743): a multicentre, 
randomised, open-label, phase 3 trial.  Lancet. 2021 Jan 30;397([ZIP_CODE]):375-386.  
 Blank CU, Rozeman EA, Fanchi LF, Sikorska K, va n de Wiel B, Kvistborg P, Krijgsman O, van 
den Braber M, Philips D, Broeks A, van Thiene n JV, Mallo HA, Adriaansz S, Ter Meulen S, 
Pronk LM, Grijpi[INVESTIGATOR_8745]-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, 
Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Neoadjuvant versus adjuvant 
ipi[INVESTIGATOR_799155]. Nat Med. 2018 
Nov;24(11):1655-1661.   Blayney JK, Ceresoli GL, Castagneto B, et al. Re sponse to chemotherapy is predictive in relation 
to longer overall survival in an  individual patient combined-analy sis with pleural mesothelioma. 
Eur J Cancer 2012; 48 (16): 2983-2992.  Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, Chaft J, Forde PM, Jones DR, Broderick SR. Initial results of pulmonary 
resection after neoadjuvant nivolumab in patien ts with resectable non- small cell lung cancer. J 
Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276.  Burt BM, Cameron RB, Mollberg NM , et al. Malignant pleural meso thelioma and the Society of 
Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac 
Cardiovasc Surg 2014; 148(1): 30-5.  Campbell N, Kindler HL. Update on malignant pl eural mesothelioma. Semin Respir Crit Care 
Med  2011; 32(1): 102-110.  Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda 
M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, 
Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, 
Kuiper M, Verbeek WH, Kok M, Van Leerda m ME, Schumacher TN, Voest EE, Haanen JB. 
Neoadjuvant immunotherapy leads to patholog ical responses in MMR-proficient and MMR-
deficient early-stage colon cancer s. Nat Med. 2020 Apr;26(4):566-576. 
 
 
 
  Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, As kin FB, Niknafs N, Smith KN, Velez MJ, Sauter 
JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, 
Velescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Methews A, Taube JM. Pathologic features of response to neoadjuvant anti-PD-[ADDRESS_1102239] ed non-small-ce ll carcinoma: a 
proposal for quantitative immune-related patholog ic response criteria (irPRC). Ann Oncol 2018 
Aug 1;29(8):1853-1860.  Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and 
angiogenesis. Cancer Re s. 2012 May 1;72(9):2162-71. 
 Fiegle E, Doleschel D, Koletnik S, Rix A, Wei skirchen R, Borkham-Kamphorst E, Kiessling F, 
Lederle W. Dual CTLA-4 and PD-L 1 Blockade Inhibits Tumor Grow th and Liver Metastasis in a 
Highly Aggressive Orthotopic Mouse Model of  Colon Cancer. Neoplas ia. 2019 Sep;21(9):932-
944.   Gordon GJ, Rockwell GN, Godfrey PA, et al. Va lidation of genomics-ba sed prognostic tests in 
malignant pleural mesothelioma. Clin Cancer Res 2005; 11:4406-14. 
 Hamid O, Robert C, Daud A, et al. Safety a nd Tumor Responses with Lambrolizumab (Anti-PD-
1) in Melanoma. N Engl J Med 2013; 369:134-44.  Harlin H. Meng Y, Peterson AC, et al. Chem okine expression in melanoma metastases 
associated with CD8+ T-cell re cruitment. Cancer Res 2009; 69, 3077–3085. 
 
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pi [INVESTIGATOR_62633], Kalhor N, Pataer A, Travis WD, 
Swisher SG, Kris MG; University of Texa s MD Anderson Lung Cancer Collaborative Group. 
Pathological response after neoadj uvant chemotherapy in resectab le non-small-cell lung cancers: 
proposal for the use of major pat hological response as a surroga te endpoint. Lancet Oncol. 2014 
Jan;15(1):e42-50.   Helm JH, Miura JT, Glenn JA, Marcus RK , Larrieux G, Jayakrishnan TT, Donahue 
AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic  review and 
meta-analysis. Ann Surg Oncol. 2015 May;22(5):1686-93.   Henley SJ, Larson TC, Wu M, et al. Mesothelioma  incidence in [ADDRESS_1102240] of 
Columbia, [LOCATION_002], 2003-2008. Int J Occu p Environ Health 2013; 19 (1): 1-10.  
 Hjerpe A, Ascoli V, Bedrossian CWM, et al. Guidelines for the cytopathologic diagnosis of 
epi[INVESTIGATOR_799156]-type malignant mesothelioma: a s econdary publication. 
Cytopathology2015; 26 (3): 142-156.   Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, 
Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, 
 
 
 
 Giles L, Kier MW, Quagliarello F, McGettigan S,  Kreider K, Annamalai L, Zhao Q, Mogg R, 
Xu W, Blumenschein WM, Yearley JH, Linett e GP, Amaravadi RK, Schuchter LM, Herati RS, 
Bengsch B, Nathanson KL, Farwell MD, Karakousis  GC, Wherry EJ, Mitchell TC. A single dose 
of neoadjuvant PD-1 blockade predicts clinical outcomes in  resectable melanoma. Nat Med. 
2019 Mar;25(3):454-461.  Husain AN, Colby [CONTACT_67382], Ordonez NG, et al. Guide lines for pathologic di agnosis of malignant 
mesothelioma: a consensus statem ent from the Internati onal  Mesothelioma Interest Group. Arch 
Pathol Lab Med 2009; 133 (8): 1317-1331.   Kepenekian V, Elias D, Passot G, Mery E,  Goere D, Delroeux D, Quenet F, Ferron 
G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani  
P, Ortega-Deballon P, Isaac S, Maurice C, Gilly FN, Glehen O; French Network for  
Rare Peritoneal Malignancies (RENAPE). Di ffuse malignant peritoneal mesothelioma: 
Evaluation of systemic chemotherapy with  comprehensive treatm ent through the RENAPE 
Database: Multi-Institutional Retrospectiv e Study. Eur J Cancer. 2016 Sep;65:69-79. doi: 
10.1016/j.ejca.2016.06.002. Epub 2016 Jul 26. PubMed PMID: 27472649.  Kindler HL, Zuo Z, Khatri A, Keck MK, Vigne swaran W, Husain AN, Seiwert TY. T-cell 
inflamed phenotype and PDL1 expression in ma lignant mesothelioma. J Clin Oncol 32:5s, 2014 
(suppl, abstr 7589)  Krug L, Pass H, Rusch V et al. Multicenter phase II trial of neoadjuvant peme trexed plus cisplatin 
followed by [CONTACT_799174].  J 
Clin Oncol. 2009; 27(18):3007-13.  
Miura JT, Johnston FM, Gamblin TC, Turaga KK.  Current trends in the management of 
malignant peritoneal mesothelioma. A nn Surg Oncol. 2014 Nov;21(12):3947-53. doi: 
10.1245/s10434-014-3803-6. Epub 2014 May 20. PubMed PMID: 24841356.  Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda  E, Husain AN, Patel JD, Rose B, Zhang SR, 
Weatherly M, Nelakuditi V, Knight Johnson A, He lgeson M, Fischer D, Desai A, Sulai N, 
Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Ki ndler HL, Churpek JE. 
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J 
Clin Oncol. [ADDRESS_1102241] 1;36(28):2863-2871.  
Powderly JD, Koeppen H, Hodi FS,  et al. Biomarkers and associa tions with the clinical activity 
of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013; 31 (suppl; abstr 3001). 
 Ray M, Kindler HL. Malignant pleural mesothel ioma: an update on biomarkers and treatment. 
Chest 2009; 136(3): 888-896.  
Ribas A, Robert C, Hodi FS, et al Association of  response to programmed death receptor 1 (PD-1) 
blockade with pembrolizumab (MK-3475 ) with an interferon-in flammatory immune gene  signature. J Clin 
Oncol 33, 2015 (suppl; abstr 3001) 
 
 
 
 
 Rusch VW, Giroux D. Do we need a revised stag ing system for malignant  pleural mesothelioma? 
Analysis of the IASLC database. Ann Cardiothoracic Surg 2012; 1(4): 438-448. 
 Saloura, V, Zuo, Z, Koeppen, H, et al. Co rrelation of T-cell inflamed phenotype with 
mesenchymal subtype, expression of PD-L1, a nd other immune checkpoints in head and neck 
cancer. J Clin Oncol 2014;  32:5s, (suppl; abstr 6009) 
 Seiwert TY, McGregor, S, Zuo Z, Khattri A, Hasi na R, Vigneswaran W, Salgia R, Husain A, 
Kindler H. T-cell inflamed phenotype, PD-L1, a nd ICOS expression identify a subgroup of 
malignant mesotheliomas amenable to imm unotherapy approaches. Proc IMIG 2014. 
 Seiwert TY, Burtness, B, Weiss J, Eder JP, Y early J, Murpy E, Nebozhyn M, McClanahan M, 
Ayers M, Lunceford J, Mehra R,Heath K, Ch eng J, Chow LQ, Inflamed-phenotype gene 
expression signatures, and in particular a γ-Interferon signature [CONTACT_799175]-PD-1 antibody pembrolizumab in PD-L 1+ HNC, ASCO Annual M eeting 2015, abstract 
6017.  Topalian SL, Taube JM, Pardoll DM. Neoa djuvant checkpoint blockade for cancer 
immunotherapy. Science 2020;367(6477).  Turaga KK, Deraco M, Alexander HR. Current  management strategi es for peritoneal 
mesothelioma. Int J Hyperthermia. 2017 Aug; 33(5):579-581. doi: 
10.1080/02656736.2017.1320591. PubMed PMID: 28664790.  Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination 
with cisplatin versus cisplatin alone in patients with malignant  pleural mesothelioma. J Clin 
Oncol 2003; 21 (14): 2636-2644.  White MG, Schulte JJ, Xue L, Berger Y, Schuite voerder D, Vining CC, Kindler HL, Husain A, 
Turaga KK, Eng OS. Heterogeneity in PD-L1 expr ession in malignant peritoneal mesothelioma 
with systemic or intraperitoneal chemot herapy. Br J Cancer. 2021 Feb;124(3):564-566.  
 Wolchok JD, Kluger H, Callahan MK, et al. Nivolu mab plus ipi[INVESTIGATOR_799157]. 
N Engl J Med 2013; 369:122-33.  Wolchok JD, Hoos A, O’day S, et al. Guidelines for the evaluation of imm une therapy activity in 
solid tumors: immune related response criteria. Clin Cancer Res 2009; 15: 7412 
 Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Pi[INVESTIGATOR_76262]  P, Sugarbaker PH. Cytoreductive surgery and 
hyperthermic intraperitoneal ch emotherapy for malignant peri toneal mesothelioma: multi-
institutional experience. J Clin Oncol. 2009 Dec 20;27(36):6237-42. doi: 
10.1200/JCO.2009.23.9640. Epub 2009 Nov 16. PubMed PMID:  19917862  
 
 
 
 Yang Z, Liu M, Yu Y, Chen T, Han Y, Zhu L, Zhao J, Fu X, Cai X. Treatment of stage III non-small cell lung cancer in  the era of immunotherapy: path ological complete response to 
neoadjuvant pembrolizumab and chemotherapy. Transl Lung Cancer Res 2020; 9(5):2059-2073. 
  12.0 APPENDIX 
12.1 ECOG Performance Status 
Grade Descriptio
n 
0 Normal activity. Fully active, able to carry on all pre-disease 
performance without restriction. 
1 Symptoms, but ambulatory. Restri cted in physically strenuous 
activity, but ambulatory and able to  carry out work of a light or 
sedentar y nature (e. g., light housework, office work). 
2 In bed <50% of the time . Ambulatory and capable of all self-care, but 
unable to carry out any work activities. Up and about more than 50% 
of wakin g hours. 
3 In bed >50% of the time. Capable of  only limited self-care, confined 
to bed or chair more than 50% of wakin g hours. 
4 100% bedridden. Completely disabled . Cannot carry on any self-care. 
Totall y confined to bed or chair. 
5 Dead. 
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:649-655, 1982. The Eastern Cooperative Onco logy Group, Robert Comis 
M.D., Group Chair. 
 
12.2 Common Terminology Criteria for Adverse Events V5.0 (CTCAE) 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 5.0 will be utilized for adverse event reporting. 
(https://ctep.cancer.gov/proto colDevelopment/elect ronic_applications/ctc.htm#ctc_60 ) 
 
12.3 Prescribing Information 
12.3.1  Nivolumab 
https://www.accessdata.fda.gov/drugsa tfda_docs/label/2018/125554s058lbl.pdf  
 
12.3.2  Ipi[INVESTIGATOR_799158]://www.accessdata.fda.gov/drugsa tfda_docs/label/2020/125377s110lbl.pdf  
 
12.4 EORTC QOL-C30 Quality of Life Survey 
https://www.eortc.org/app/uploads/site s/2/2018/08/Specimen-QLQ-C30-English.pdf  